GlobalData, the industry analysis specialist, has released its latest report: “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – France”. The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in France. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.
The population of France in 2016 was 64.6 million, which increased gradually from 62.5 million in 2009. The French National Authority for Health (Haute Autorité de Santé or HAS) and the Commission for Economic Evaluation and Public Health (Commission d’Évaluation Économique et de Santé Publique; CEESP) started an economic evaluation in October 2013, for the assessment or reassessment of drugs and medical devices under certain circumstances.
In 2016, the government spent 11.6% of GDP on healthcare expenditure and exported $29.4 billion of pharmaceutical products. The pharmaceutical market in France was worth $35.59 billion in 2016, with a growth in generic drugs market. The volume of generic drug market increased from 23.6% in 2009 to 36.3% in 2016. The medical device market was valued at $18.2 billion in 2016 and is projected to grow at a CAGR of 4% to $22.5 billion by 2021. These positive growth trends can be primarily attributed to:
- An increasingly elderly population
- Universal health coverage
- Government initiatives